Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy

Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and...

Full description

Bibliographic Details
Main Authors: Kent Y. Feng, MD, Rahul S. Loungani, MD, Vishal N. Rao, MD, MPH, Chetan B. Patel, MD, Michel G. Khouri, MD, G. Michael Felker, MD, MHS, Adam D. DeVore, MD, MHS
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:JACC. CardioOncology
Subjects:
amyloidosis
biomarkers
cardiac magnetic resonance
cardiomyopathy
echocardiography
nuclear imaging
Online Access:http://www.sciencedirect.com/science/article/pii/S2666087319300912
Description
Summary:Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.
ISSN:2666-0873

Similar Items